Targeting breast cancer vaccines to dendritic cells: Improved immunological responses with less protein?

Breast Cancer Research

Volumn 14, Issue 3, 2012, Pages

  Armstrong, Anne C ^a   Gilham, David E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; HYBRID PROTEIN;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; BREAST CANCER; BREAST METASTASIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL MATURATION; DENDRITIC CELL; DRUG POTENCY; EDITORIAL; EFFECTOR CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); T LYMPHOCYTE; VACCINATION; ANIMAL; BREAST TUMOR; FEMALE; IMMUNOLOGY; MOUSE;

ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; MICE; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 84861709327     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3184     Document Type: Editorial

References (16)

1. Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keler T, Steinman RM. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 2012, 14:R39. 10.1186/bcr3135, 22397502.
2. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R, . Herceptin Adjuvant(HERA) Trial Study Team Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011, 12:236-244. 10.1016/S1470-2045(11)70033-X, 21354370, Herceptin Adjuvant(HERA) Trial Study Team.
3. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, . HERA study team 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36. 10.1016/S0140-6736(07)60028-2, 17208639, HERA study team.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
5. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368. 10.1634/theoncologist.2008-0230, 19346299.
6. Wright SE. Immunotherapy of breast cancer. Expert Opin Biol Ther 2012, 12:479-490. 10.1517/14712598.2012.665445, 22413825.
7. Clive KS, Tyler JA, Clifton GT, Holmes JP, Ponniah S, Peoples GE, Mittendorf EA. The GP2 peptide: A HER2/neu-based breast cancer vaccine. J Surg Oncol 2012, 105:452-458. 10.1002/jso.21723, 22441896.
8. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 2008, 57:1511-1521. 10.1007/s00262-008-0540-3, 18536917.
9. Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S, Peoples GE. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012, 118:2594-2602. 10.1002/cncr.26574, 21989902.
10. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012, 104:599-613. 10.1093/jnci/djs033, 22395641.
11. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, Schlesinger SJ, Steinman RM. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med 2012, 271:183-192. 10.1111/j.1365-2796.2011.02496.x, 22126373.
12. Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, Arrey F, Park CG, Steinman RM, Munz C. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 2008, 112:1231-1239. 10.1182/blood-2008-03-148072, 2515117, 18519810.
13. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009, 206:1589-1602. 10.1084/jem.20090247, 2715098, 19564349.
14. Castro FV, Al-Muftah M, Mulryan K, Jiang HR, Drijfhout JW, Ali S, Rutkowski AJ, Kalaitsidou M, Gilham DE, Stern PL. Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy. Cancer Immunol Immunother 2011,
15. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994, 54:16-20.
16. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, Fu YX. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18:160-170. 2923645, 20708157.